 | Up a level |
Asemissen, A. M., Scheid, C., Leypoldt, L., Schieferdecker, A., Besemer, B., Blau, I. -W., Goerner, M., Ko, Y. -D., Haenel, M., Duerig, J., Staib, P., Salwender, H., Mann, C., Munder, M., Graeven, U., Peceny, R., Lutz, R., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. and Weisel, K. (2020). Mobilization of autologous stem cells under induction therapy with Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone (Isa-KRd) in high risk myeloma patients: First results of the GMMG-CONCEPT trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 94 - 96. BASEL: KARGER. ISSN 2296-5262
Weisel, K., Salwender, H., Scheid, C., Zago, M., Besemer, B., Haenel, M., Duerig, J., Munder, M., Lindemann, H. -W, Seckinger, A., Kunz, C., Benner, A., Hose, D., Jauch, A., Kanz, L. and Goldschmidt, H. (2018). Pomalidomide, cyclophosphamide and dexamethasone in case of suboptimal response to pomalidomide and dexamethasone alone in relapsed and/or refractory multiple myeloma: Final results of the GMMG-PERSPECTIVE trial. Oncol. Res. Treat., 41. S. 133 - 135. BASEL: KARGER. ISSN 2296-5262